References in periodicals archive ?
"The issuance of this patent serves to solidify Collateral Therapeutics' proprietary position in angiogenic gene therapy for the non-surgical treatment of cardiovascular disease," observed Jack W.
Collateral has assembled a broad portfolio of therapeutic genes for use in the development of angiogenic gene therapy products.
In November 1999, Collateral announced the development of a new class of non-surgical angiogenic gene therapy products using the company's dual recombinant angiogenic gene therapy technology.